Target Name: RESF1
NCBI ID: G55196
Other Name(s): Uncharacterized protein KIAA1551 | uncharacterized protein C12orf35 | retroelement silencing factor 1 | C12orf35 | UTA2-1 | GET | Retroelement silencing factor 1 | gonad expressed transcript | Uncharacterized protein C12orf35 | KIAA1551 | RESF1_HUMAN

KIAA1551: A Potential Drug Target for Cell Division and Cancer

Resveratrol is a naturally occurring compound that has been shown to have a wide range of therapeutic potential due to its anti-inflammatory and antioxidant properties. One of the Resveratrol-derived compounds that has received particular attention is KIAA1551, a protein that is expressed in various tissues throughout the body. KIAA1551 has been shown to play a crucial role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

The protein KIAA1551 is a key regulator of the cell cycle and has been shown to have a direct impact on the distribution and activity of other proteins in the cell. Its role in cell division and the regulation of cell cycle progression has been well-documented in various studies, and it is believed to be a potential drug target in the near future.

Research on KIAA1551

The study of KIAA1551 has been ongoing for several years, and there is a growing body of research that has shed light on its various functions and potential as a drug target. One of the main focuses of research has been to understand the role of KIAA1551 in cell division and the regulation of the cell cycle.

Studies have shown that KIAA1551 plays a critical role in the distribution and activity of other proteins in the cell. It has been shown to interact with various proteins, including the transcription factor TP50 and the protein kinase B-actinin. These interactions are thought to play a role in the regulation of cell division and the distribution of proteins throughout the cell.

Additionally, studies have shown that KIAA1551 is involved in the regulation of the cell cycle at various stages, including G1, S, and G2. It has been shown to accumulate in the G2 phase and to be involved in the transition from G2 to S phase. This may have implications for the regulation of cell division and the risk of cancer.

Another area of research on KIAA1551 has been its potential as a drug target. Many diseases, including neurodegenerative diseases and cancer, are characterized by the accumulation of misfolded proteins and the disruption of normal cellular processes. KIAA1551 has been shown to be involved in the regulation of protein stability and may be a potential target for drugs that are designed to treat these diseases.

Preclinical studies have shown that KIAA1551 can be targeted with small molecules and antibodies to induce a conformational change that results in the inhibition of its activity. This suggests that KIAA1551 may be an attractive target for drug development in the near future.

The potential implications of KIAA1551 as a drug target are significant. If KIAA1551 is found to be a reliable drug target, it may be used to treat a variety of diseases that are characterized by the accumulation of misfolded proteins and the disruption of normal cellular processes.

Conclusion

In conclusion, KIAA1551 is a protein that has received significant attention in recent years due to its role in the regulation of cell division and the cell cycle. Its role in these processes has been well-documented in various studies, and it is believed to be a potential drug target in the near future. Further research is needed to fully understand the functions of KIAA1551 and its potential as a drug target. If its potential as a drug target is confirmed, KIAA1551 may be an attractive target for the development of new treatments for a variety of diseases.

Protein Name: Retroelement Silencing Factor 1

Functions: Plays a role in the regulation of imprinted gene expression, regulates repressive epigenetic modifications associated with SETDB1. Required for the recruitment or accumulation of SETDB1 to the endogenous retroviruses (ERVs) and maintenance of repressive chromatin configuration, contributing to a subset of the SETDB1-dependent ERV silencing in embryonic stem cells

More Common Targets

RESP18 | REST | RET | Retinoid acid receptor | Retinoid RXR receptor | Retinol dehydrogenase | RETN | RETNLB | RETREG1 | RETREG2 | RETREG3 | RETSAT | REV1 | REV3L | Reverse transcriptase (Telomerase) | REX1BD | REXO1 | REXO1L1P | REXO1L2P | REXO1L6P | REXO1L8P | REXO2 | REXO4 | REXO5 | RFC1 | RFC2 | RFC3 | RFC4 | RFC5 | RFESD | RFESDP1 | RFFL | RFK | RFLNA | RFLNB | RFNG | RFPL1 | RFPL1S | RFPL2 | RFPL3 | RFPL3S | RFPL4A | RFPL4AL1 | RFPL4B | RFT1 | RFTN1 | RFTN2 | RFWD3 | RFX complex | RFX1 | RFX2 | RFX3 | RFX3-DT | RFX4 | RFX5 | RFX5-AS1 | RFX6 | RFX7 | RFX8 | RFXANK | RFXAP | RGCC | RGL1 | RGL2 | RGL3 | RGL4 | RGMA | RGMB | RGMB-AS1 | RGN | RGP1 | RGPD1 | RGPD2 | RGPD3 | RGPD4 | RGPD4-AS1 | RGPD5 | RGPD6 | RGPD8 | RGR | RGS1 | RGS10 | RGS11 | RGS12 | RGS13 | RGS14 | RGS16 | RGS17 | RGS18 | RGS19 | RGS2 | RGS20 | RGS21 | RGS22 | RGS3 | RGS4 | RGS5 | RGS6 | RGS7 | RGS7BP